Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAethlon Medical Inc

Aethlon Medical Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
5.47 USD 0.16 ( 3.01%)
Last update at 2026-11-06T21:00:00Z
VOLUME
6390
Market Cap
1.05M

Momentum Score

…

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.36
Low
5.47
High
52 Week Price Range
1.45
Low
41.35
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aethlon Medical develops extracorporeal devices such as the Hemopurifier to remove viruses and disease-associated exosomes from blood for infectious disease and oncology applications. Long-term growth may be supported by successful clinical trials and regulatory approvals, broader clinical adoption of pathogen/exosome removal as an adjunct therapy, and potential commercial partnerships.

Key risks include limited clinical evidence and regulatory uncertainty for its Hemopurifier, constrained financial resources requiring additional capital, and competitive and commercialization challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.31
Dividend Yield
-
Revenue TTM
0.57M
Revenue Per Share
0.24
Gross Profit TTM
0.57M
Debt / Equity
0.07
ROE
-160.91%
Net Debt
-4.69M
ROCE
-146.06%
Diluted EPS TTM
-13.98

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -7.15M -13.39M -12.21M -12.03M -10.42M
Minority interest - - - 0.00M 0.00M
Net income -7.15M -13.39M -12.21M -143.18M -10.42M
Selling general administrative 4.04M 9.34M 7.01M 12.47M 10.72M
Selling and marketing expenses 3.25M - 5.63M - -
Gross profit - -0.34M -0.36M -4442.98M 0.29M
Reconciled depreciation 0.32M 0.34M 0.36M 0.24M 0.12M
Ebit -7.14M -13.38M -12.64M -11.90M -10.54M
Ebitda -6.81M -13.04M -12.28M -11.76M -10.42M
Depreciation and amortization 0.32M 0.34M 0.36M 0.14M 0.12M
Operating income -7.29M -9.34M -12.64M -11.90M -10.42M
Other operating expenses 7.29M 9.34M 12.64M 12.47M 10.72M
Interest expense 0.01M 0.01M - 131.15M -0.12M
Interest income 0.16M 0.30M 0.43M 0.01M -
Net interest income 0.14M 0.29M 0.43M 0.01M -
Income tax expense - - 0.00M 131.15M -0.00M
Total revenue 0.00M 0.00M 0.00M 0.57M 0.29M
Total operating expenses 7.29M 9.34M 12.64M 12.47M 10.72M
Cost of revenue - 0.34M 0.36M 4443.55M 4625.80M
Total other income expense net 0.14M -4.05M 0.43M -0.13M 4.79M
Net income from continuing ops -7.15M -13.39M -12.21M -12.03M -10.42M
Net income applicable to common shares - - - -12.03M -10.42M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 6.33M 7.36M 8.25M 17.51M 19.42M
Intangible assets - 0.00M 0.00M 0.00M 0.00M
Other current assets 0.54M 0.45M 0.78M 0.56M 0.96M
Total liab 1.45M 2.24M 2.48M 2.44M 2.43M
Total stockholder equity 4.89M 5.12M 5.77M 15.06M 17.13M
Other current liab 0.73M 1.05M 0.76M 0.59M 0.85M
Common stock 0.00M 0.00M 0.00M 0.02M 0.02M
Capital stock 0.00M 0.00M 0.00M 0.02M 0.02M
Retained earnings -175.11M -167.95M -154.57M -142.36M -130.33M
Other assets - - 0.00M 0.12M 0.12M
Cash 5.03M 5.50M 5.44M 14.53M 17.07M
Total current liabilities 1.45M 1.90M 1.83M 1.51M 1.82M
Current deferred revenue - - - 0.21M 0.34M
Net debt -4.69M -4.85M -4.50M -13.32M -16.34M
Short term debt 0.34M 0.31M 0.29M 0.27M 0.13M
Short long term debt total 0.34M 0.65M 0.94M 1.21M 0.73M
Other stockholder equity 180.02M 173.09M 160.34M 163.55M 147.45M
Property plant equipment - - - 2.30M 1.14M
Total current assets 5.57M 5.95M 6.23M 15.09M 18.16M
Net tangible assets - - - 15.06M 17.13M
Net receivables - - - 0.00M 0.13M
Accounts payable 0.38M 0.53M 0.78M 0.43M 0.50M
Accumulated other comprehensive income -0.03M -0.02M -0.01M -6.14M -
Non currrent assets other 0.10M 0.03M 0.03M 0.12M 0.12M
Non current assets total 0.76M 1.41M 2.02M 2.42M 1.26M
Capital lease obligations 0.34M 0.65M 0.94M 1.21M 0.73M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - 0.00M -0.25M -0.94M -0.35M
Change to liabilities - - - -0.52M 0.33M
Total cashflows from investing activities -0.00M - -0.25M -0.94M -0.35M
Total cash from financing activities 6.52M 7.73M 1.29M 8.91M 17.37M
Change to operating activities - - - 0.46M -0.60M
Net income -7.15M -13.39M -12.21M -12.03M -10.42M
Change in cash -0.47M 0.07M -9.09M -2.54M 7.25M
Begin period cash flow 5.60M 5.53M 14.62M 17.16M 9.91M
End period cash flow 5.13M 5.60M 5.53M 14.62M 17.16M
Total cash from operating activities -7.00M -7.65M -10.13M -10.51M -9.77M
Issuance of capital stock 6.90M 3.54M 1.32M 8.93M 17.46M
Depreciation 0.32M 0.34M 0.36M 0.24M 0.12M
Change to inventory - - - 0.46M -
Change to account receivables - - 0.00M 0.13M 0.02M
Other cashflows from financing activities -0.14M 4.19M -0.03M -0.01M -0.09M
Change to netincome - - - 1.22M 0.78M
Capital expenditures 0.00M 0.00M 0.25M 0.94M 0.35M
Change in working capital -0.74M 0.09M 0.48M 0.07M -0.25M
Stock based compensation 0.28M 0.42M 1.22M 1.05M 0.75M
Other non cash items 0.29M 4.89M 0.02M -46.60M 0.03M
Free cash flow -7.00M -7.65M -10.38M -11.45M -10.12M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AEMD
Aethlon Medical Inc		 0.16
3.01%		 5.47 - 0.21 2.37 0.21 18.80 44.52
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Aethlon Medical Inc

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.

11555 Sorrento Valley Road, San Diego, CA, United States, 92121

619 941 0360

https://www.aethlonmedical.com

9

Name Title Year Born
Dr. Charles J. Fisher Jr., M.D. CEO, Director & Member of Extracorporeal Therapy Advisory Board 1947
Mr. Steven P. Larosa M.D. Chief Medical Officer & Acting Chief Scientific Officer 1967
Mr. Guy F. Cipriani BS (Eng.), MBA Sr. VP, Chief Bus. Officer & Director 1970
Mr. James B. Frakes M.B.A. CFO, Sr. VP of Fin. & Sec. 1957
Mr. Sunil Sawhney Head of Clinical Studies NA
Dr. Richard H. Tullis Ph.D. Consultant 1945
Mr. Guy F. Cipriani BS (Eng.), MBA Chief Operating Officer 1971
Dr. Steven P. LaRosa M.D. Chief Medical Officer 1967
Mr. James B. Frakes M.B.A. Interim CEO, CFO, Secretary & Director 1957
Dr. Lee D. Arnold Ph.D. Chief Scientific Officer 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…